Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE We engineer human liver organoids to combine four common cholangiocarcinoma mutations (TP53, PTEN, SMAD4, and NF1). 31130514 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease BEFREE In contrast, mutations of phosphatase and tensin homolog (PTEN) and tumor protein 53 (TP53) appeared to be higher in HGG tumors in CC patients than in their AA counterparts. 29599344 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE Only a few studies have evaluated the clinicopathological significance of the p53 protein expression and s-p53-Abs level in patients with cholangiocarcinoma. 28508195 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE Besides, the expression of CXCL7 was significantly associated with the Ki67 expression, but not associated with CA199, AFP, or P53 expression in cholangiocarcinoma. 27959418 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE These data indicate that p53 is important for the activation of autophagy in nutrient-deprived cholangiocarcinoma cells, and thus contributes to cell survival and chemoresistance. 28789429 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE Here we characterize Notch in human-resected CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted to biliary epithelia and CC induced using the hepatocarcinogen thioacetamide. 27791012 2016
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. 24204826 2013
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease CTD_human Exome sequencing of liver fluke-associated cholangiocarcinoma. 22561520 2012
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma. 22230750 2012
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. 20422343 2010
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE Of the molecular markers which have been investigated to date, p53 mutation, cyclins, proliferation indices, mucins, CA19-9, CRP and aneuploidy appear to hold significant potential as predictors of outcome in CC. 18938071 2009
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease LHGDN Expression of P53 protein could not act as an independent index to estimate the prognosis of cholangiocarcinoma. 16937443 2006
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease CTD_mouse Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. 16818635 2006
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE Expression of P53 protein could not act as an independent index to estimate the prognosis of cholangiocarcinoma. 16937443 2006
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE Five non-silent p53 mutations were found, including three new frameshift mutations and two new intron mutations which have not previously been reported in cholangiocarcinoma. 16596244 2006
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease BEFREE The findings of previous p53 studies and their relevance in human cholangiocarcinoma are summarised. 15998419 2005
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE A series of nine CC, 15 HCC-CC and three separated HCC and CC lesions ('collision tumors') were screened for loss of heterozygosity (LOH) using 400 microsatellite markers and for p53 and beta-catenin mutations. 15288479 2004
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease LHGDN PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. 12829999 2003
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease BEFREE Accumulation of multiple genetic alterations are involved in the tumorigenesis of CC, of which genetic alterations of APC and DCC occur at a relatively early stage, and of OGG1 and p53 occur at a relatively late stage during development of CC. 11260864 2001
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease BEFREE Ki-67, bcl-2, p53 or DNA fragmentation were not significantly different in nontumorous liver tissue from patients with and without CC. 11168786 2001
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE We investigated the occurrence of K-ras codon 12 and 13 mutations, p53 protein accumulation, and Ki-67 expression in tumor tissue from PSC patients (n=33) who had developed cholangiocarcinoma, using bile duct specimens exised at liver transplantation of PSC patients without cholangiocarcinoma (n=15) as controls 10735605 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease BEFREE The presence of TP53 mutations or upregulation of MDM2 gene expression in 9 of the 13 cholangiocarcinomas strongly supports that the impairment of the p53 pathway is an important and specific step in cholangiocarcinoma pathogenesis. 10718212 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 AlteredExpression disease BEFREE The incidence of p53 mutations was 33.3% in CC and 42.9% in GBC. p53 protein overexpression was observed in 60% CC biopsy specimens. 10227722 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 Biomarker disease BEFREE We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver. 10362118 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.600 GeneticVariation disease BEFREE Significantly more cholangiocarcinomas from the West Virginia group were p53-immunohistochemical-positive than from the non-West Virginia group (67% vs. 20%; p < 0.05). p53 mutations did not differ in the 2 groups in respect to site or specific type. 9833761 1998